Saltar al contenido
Merck

MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression.

Cell reports (2022-06-02)
Celeste Giansanti, Valentina Manzini, Antje Dickmanns, Achim Dickmanns, Maria Dilia Palumbieri, Andrea Sanchi, Simon Maria Kienle, Sonja Rieth, Martin Scheffner, Massimo Lopes, Matthias Dobbelstein
RESUMEN

The MDM2 oncoprotein antagonizes the tumor suppressor p53 by physical interaction and ubiquitination. However, it also sustains the progression of DNA replication forks, even in the absence of functional p53. Here, we show that MDM2 binds, inhibits, ubiquitinates, and destabilizes poly(ADP-ribose) polymerase 1 (PARP1). When cellular MDM2 levels are increased, this leads to accelerated progression of DNA replication forks, much like pharmacological inhibition of PARP1. Conversely, overexpressed PARP1 restores normal fork progression despite elevated MDM2. Strikingly, MDM2 profoundly reduces the frequency of fork reversal, revealed as four-way junctions through electron microscopy. Depletion of RECQ1 or the primase/polymerase (PRIMPOL) reverses the MDM2-mediated acceleration of the nascent DNA elongation rate. MDM2 also increases the occurrence of micronuclei, and it exacerbates camptothecin-induced cell death. In conclusion, high MDM2 levels phenocopy PARP inhibition in modulation of fork restart, representing a potential vulnerability of cancer cells.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
cOmplete, Mini, Cóctel de inhibidores de proteasas, Tablets provided in a glass vial
Sigma-Aldrich
(S)-(+)-Camptothecin, ≥90% (HPLC), powder
Sigma-Aldrich
Ribonucleasa A from bovine pancreas, Type I-AS, 50-100 Kunitz units/mg protein